doxazosin has been researched along with Urinary Retention in 16 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Urinary Retention: Inability to empty the URINARY BLADDER with voiding (URINATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS)." | 9.19 | Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial. ( Çelik, O; Eryıldırım, B; Faydacı, G; Tarhan, F; Tosun, Ç, 2014) |
| "To evaluate the efficacy of modified-release doxazosin 4 mg in the treatment of patients with acute urinary retention (AUR) due to benign prostate gland hyperplasia (BPH)." | 9.13 | Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. ( López, C; Ortiz, M; Pacheco, JJ; Prieto, L; Romero, J, 2008) |
| "Prospective and randomised study to assess the effectiveness of doxazosin in sustained release formulation in Acute Urinary Retention (AUR) treatment due to benign prostatic hyperplasia (BPH)." | 9.11 | [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect]. ( Arango Toro, O; Bielsa Gali, O; Cañis Sánchez, D; Cortadellas Angel, R; Gelabert Mas, A; Lorente Garín, JA, 2004) |
| "To report an integrated analysis of two previous studies fully characterizing the clinical utility of the controlled-release gastrointestinal therapeutic system (GITS) formulation of doxazosin in the treatment of benign prostatic hyperplasia (BPH)." | 9.09 | A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. ( Andersen, M; Dahlstrand, C; Gratzke, P; Høye, K; Kirby, RS, 2001) |
| "We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS)." | 5.19 | Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial. ( Çelik, O; Eryıldırım, B; Faydacı, G; Tarhan, F; Tosun, Ç, 2014) |
| "To evaluate the efficacy of modified-release doxazosin 4 mg in the treatment of patients with acute urinary retention (AUR) due to benign prostate gland hyperplasia (BPH)." | 5.13 | Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. ( López, C; Ortiz, M; Pacheco, JJ; Prieto, L; Romero, J, 2008) |
| "Prospective and randomised study to assess the effectiveness of doxazosin in sustained release formulation in Acute Urinary Retention (AUR) treatment due to benign prostatic hyperplasia (BPH)." | 5.11 | [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect]. ( Arango Toro, O; Bielsa Gali, O; Cañis Sánchez, D; Cortadellas Angel, R; Gelabert Mas, A; Lorente Garín, JA, 2004) |
| "To report an integrated analysis of two previous studies fully characterizing the clinical utility of the controlled-release gastrointestinal therapeutic system (GITS) formulation of doxazosin in the treatment of benign prostatic hyperplasia (BPH)." | 5.09 | A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. ( Andersen, M; Dahlstrand, C; Gratzke, P; Høye, K; Kirby, RS, 2001) |
| "Acute urinary retention is a urological emergency in men and requires urgent catheterisation." | 2.50 | The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. ( Fisher, E; Omar, MI; Subramonian, K, 2014) |
| "To evaluate the efficacy and adverse effects of doxazosin for treating lower urinary tract symptoms (LUTS) compatible with benign prostatic obstruction (BPO)." | 2.42 | Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. ( Howe, RW; MacDonald, R; Wilt, TJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, Y | 1 |
| Bai, F | 1 |
| Zhang, N | 1 |
| Wu, H | 1 |
| Tarhan, F | 1 |
| Çelik, O | 1 |
| Tosun, Ç | 1 |
| Faydacı, G | 1 |
| Eryıldırım, B | 1 |
| Fisher, E | 1 |
| Subramonian, K | 1 |
| Omar, MI | 1 |
| Prieto, L | 1 |
| Romero, J | 1 |
| López, C | 1 |
| Ortiz, M | 1 |
| Pacheco, JJ | 1 |
| Merrick, GS | 1 |
| Butler, WM | 1 |
| Wallner, KE | 1 |
| Lief, JH | 1 |
| Galbreath, RW | 1 |
| Hershkovitz, A | 1 |
| Manevitz, D | 1 |
| Beloosesky, Y | 1 |
| Gillon, G | 1 |
| Brill, S | 1 |
| O'Reilly, P | 1 |
| Cain, MP | 1 |
| Wu, SD | 1 |
| Austin, PF | 1 |
| Herndon, CD | 1 |
| Rink, RC | 1 |
| Lorente Garín, JA | 1 |
| Cañis Sánchez, D | 1 |
| Arango Toro, O | 1 |
| Bielsa Gali, O | 1 |
| Cortadellas Angel, R | 1 |
| Gelabert Mas, A | 1 |
| Verhamme, KM | 1 |
| Bosch, RJ | 1 |
| Sturkenboom, MC | 1 |
| MacDonald, R | 1 |
| Wilt, TJ | 1 |
| Howe, RW | 1 |
| Wyllie, M | 1 |
| Yucel, S | 1 |
| Akkaya, E | 1 |
| Guntekin, E | 1 |
| Kukul, E | 1 |
| Akman, S | 1 |
| Melikoglu, M | 1 |
| Baykara, M | 1 |
| Szabadi, E | 1 |
| Kirby, RS | 1 |
| Andersen, M | 1 |
| Gratzke, P | 1 |
| Dahlstrand, C | 1 |
| Høye, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for doxazosin and Urinary Retention
| Article | Year |
|---|---|
The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Doxazosin; Humans; Indoles; Male | 2014 |
Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Drug Combinations; Enzyme Inhibit | 2004 |
7 trials available for doxazosin and Urinary Retention
| Article | Year |
|---|---|
Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Drug Administration Schedule; Humans; Isos | 2014 |
Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; D | 2008 |
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; H | 2002 |
Medical treatment for urinary retention in rehabilitating elderly women: is it necessary?
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Female; Humans; Pos | 2003 |
Alpha blocker therapy for children with dysfunctional voiding and urinary retention.
Topics: Adolescent; Adrenergic alpha-Antagonists; Antibiotic Prophylaxis; Child; Child, Preschool; Dose-Resp | 2003 |
[Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect].
Topics: Acute Disease; Aged; Doxazosin; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Urinary Ca | 2004 |
A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Met | 2001 |
7 other studies available for doxazosin and Urinary Retention
| Article | Year |
|---|---|
Analysis of Voiding Impairment after Prostate Biopsy and the Effect of Doxazosin Treatment: Outcomes from a Regional Cancer Center.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Humans; Image-Guided Biopsy; Male; Postope | 2022 |
When you just can't go: my patient, a 63-year old stockbroker, recalled his experience with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male | 2009 |
Pharmaceutical review.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neo | 2003 |
Finasteride in benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Acute Disease; Adrenergic alpha-Antagonists; Cohort Studies; Doxazosin | 2004 |
Blood pressure and urologists: like oil and water?
Topics: Blood Pressure; Doxazosin; Humans; Male; Prostatic Hyperplasia; Urinary Retention; Vasodilator Agent | 2004 |
Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study.
Topics: Adrenergic alpha-Antagonists; Biofeedback, Psychology; Child; Child, Preschool; Doxazosin; Female; H | 2005 |
Doxazosin for reboxetine-induced urinary hesitancy.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents; Doxazosin; Humans; Male; Middle Aged; Morpholin | 1998 |